Sugi Predict

Sugi Predict / Compounds / Dl-Phenylalanine

Dl-Phenylalanine

Dl-Phenylalanine

SCHEMBL3630630

NC(=O)CCC(N)C(=O)O.NC(Cc1ccccc1)C(=O)O

nearest known ligand 0.73

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC7A5 Q01650 3/20 0.73
▸ ALPI P09923 1/20 0.73
▸ PKM P14618 1/20 0.73
▸ PTGS1 P23219 1/20 0.73
▸ XIAP P98170 1/20 0.73
▸ ALOX15 P16050 1/20 0.63
▸ BLM P54132 1/20 0.63
▸ PMP22 Q01453 1/20 0.63
▸ KMT2A Q03164 1/20 0.63
▸ SLC1A3 P43003 2/20 0.54
▸ SLC1A2 P43004 2/20 0.54
▸ SLC1A1 P43005 2/20 0.54
▸ SLC15A1 P46059 1/20 0.54
▸ LTA4H P09960 2/20 0.51
▸ NOS3 P29474 3/20 0.50
▸ NOS1 P29475 3/20 0.50
▸ NOS2 P35228 3/20 0.50
▸ TPH1 P17752 2/20 0.50
▸ PTPN1 P18031 1/20 0.50
▸ GRIA2 P42262 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenylalanine SCHEMBL1675409 1.00 SLC7A5 (0.73) SLC7A5ALPIPKMPTGS1XIAP
Phenylalanine SCHEMBL10428543 0.94 SLC7A5 (0.65) SLC7A5ALPIPKMPTGS1XIAP
Dl-Phenylalanine SCHEMBL21905169 0.94 SLC7A5 (0.65) SLC7A5ALPIPKMPTGS1XIAP
Dl-Phenylalanine SCHEMBL10428542 0.94 SLC7A5 (0.65) SLC7A5ALPIPKMPTGS1XIAP
Phenylalanine SCHEMBL792008 0.94 SLC7A5 (0.65) SLC7A5ALPIPKMPTGS1XIAP
Dl-Phenylalanine SCHEMBL28495410 0.94 SLC7A5 (0.65) SLC7A5ALPIPKMPTGS1XIAP
Phenylalanine SCHEMBL4287332 0.93 SLC7A5 (0.63) SLC7A5ALPIPKMPTGS1XIAP
Tyrosine SCHEMBL21097842 0.93 SLC7A5 (0.69) SLC7A5ALPIPKMPTGS1XIAP
Dl-Phenylalanine SCHEMBL27597221 0.89 SLC7A5 (0.58) SLC7A5ALPIPKMPTGS1XIAP
Dl-Phenylalanine SCHEMBL28638756 0.88 SLC7A5 (0.61) SLC7A5ALPIPKMPTGS1XIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130078732-A1 METHODS FOR DIAGNOSING IMPENDING JOINT FAILURE GUFFEY WENDELL RAY (US) 2013-03-28 — — US claimed
EP-2391889-A2 METHODS FOR DIAGNOSING IMPENDING JOINT FAILURE Nestec S.A. (CH) 2011-12-07 — — EP claimed
WO-2010087991-A2 METHODS FOR DIAGNOSING IMPENDING JOINT FAILURE NESTEC S.A. (CH) 2010-08-05 — — WO claimed
US-20030104389-A1 Synthesis of biologically active compounds in cells SERGEEV PAVEL (CH) 2003-06-05 — — US claimed
EP-1208219-A1 SYNTHESIS OF BIOLOGICALLY ACTIVE COMPOUNDS IN CELLS Sergeev, Pavel (CH) 2002-05-29 — — EP claimed
WO-2000061775-A1 SYNTHESIS OF BIOLOGICALLY ACTIVE COMPOUNDS IN CELLS SERGEEV PAVEL (CH) 2000-10-19 — — WO claimed
US-20240325561-A1 PEGYLATED DRUG-LINKERS FOR IMPROVED LIGAND-DRUG CONJUGATE PHARMACOKINETICS SEAGEN INC (US) 2024-10-03 — — US disclosed
US-20240156969-A1 CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS SEAGEN INC (US) 2024-05-16 — — US disclosed
WO-2024083953-A1 NOVEL ANTI-TPBG ANTIBODY AND ANTIBODY-DRUG-CONJUGATES BASED THEREON, THERAPEUTIC METHODS AND USES THEREOF TUBULIS GMBH (DE) 2024-04-25 — — WO disclosed
WO-2024083926-A1 NOVEL ANTIBODY DRUG CONJUGATES WITH NOVEL NAPI2B ANTIBODIES, THERAPEUTIC METHODS AND USES THEREOF TUBULIS GMBH (DE) 2024-04-25 — — WO disclosed
WO-2023220730-A1 DEGRADABLE COMPOSITE AND METHOD OF FABRICATION 206 ORTHO, INC. (US) 2023-11-16 — — WO disclosed
US-11793880-B2 Conjugates of quaternized tubulysin compounds SEAGEN INC. (US) 2023-10-24 — — US disclosed
US-20230330258-A1 CONJUGATES COMPRISING A PHOSPHORUS (V) AND A DRUG MOIETY TUBULIS GMBH (DE) 2023-10-19 — — US disclosed
US-20060275371-A1 Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells UNIVERSITY, STANFORD 2006-12-07 — — US disclosed
US-20050026143-A1 Synthesis of biologically active compounds in cells SERGEEV PAVEL (CH) 2005-02-03 — — US disclosed
CN-1558947-A Gene of peptide-producing enzyme, and process for producing dipeptide ֮����ʽ���� 2004-12-29 — — CN disclosed
US-6831071-B2 Oligonucleotide sequences for use as viricide or antitumor agents SERGEEV PAVEL (CH) 2004-12-14 — — US disclosed
US-20030104389-A1 Synthesis of biologically active compounds in cells SERGEEV PAVEL (CH) 2003-06-05 — — US disclosed
EP-1208219-A1 SYNTHESIS OF BIOLOGICALLY ACTIVE COMPOUNDS IN CELLS Sergeev, Pavel (CH) 2002-05-29 — — EP disclosed
WO-2000061775-A1 SYNTHESIS OF BIOLOGICALLY ACTIVE COMPOUNDS IN CELLS SERGEEV PAVEL (CH) 2000-10-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230330258-A1 CONJUGATES COMPRISING A PHOSPHORUS (V) AND A DRUG MOIETY CALCR, BCR, PTH1R SLC7A5 955/4885ALPI 182/4885PKM 1744/4885
US-20240156969-A1 CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS LCK, UACA, TEKT1 SLC7A5 436/4885ALPI 2889/4885PKM 4156/4885
US-20240325561-A1 PEGYLATED DRUG-LINKERS FOR IMPROVED LIGAND-DRUG CONJUGATE PHARMACOKINETICS EGFR, HDGF, CD47 SLC7A5 316/4885ALPI 1040/4885PKM 1079/4885
US-20050026143-A1 Synthesis of biologically active compounds in cells FBL, RNGTT, NOP2 SLC7A5 2697/4885ALPI 2450/4885PKM 2535/4885
US-11793880-B2 Conjugates of quaternized tubulysin compounds LCK, UACA, TEKT1 SLC7A5 436/4885ALPI 2889/4885PKM 4156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.